Rosalind Advisors Inc. Grows Stock Position in Profound Medical Corp. (NASDAQ:PROF)

Rosalind Advisors Inc. raised its holdings in Profound Medical Corp. (NASDAQ:PROF - Free Report) by 42.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 692,185 shares of the company's stock after acquiring an additional 206,212 shares during the period. Profound Medical accounts for about 2.6% of Rosalind Advisors Inc.'s holdings, making the stock its 15th biggest position. Rosalind Advisors Inc. owned 2.30% of Profound Medical worth $5,198,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Raymond James Trust N.A. boosted its holdings in Profound Medical by 14.3% in the third quarter. Raymond James Trust N.A. now owns 12,000 shares of the company's stock valued at $96,000 after acquiring an additional 1,500 shares during the last quarter. MTM Investment Management LLC raised its holdings in shares of Profound Medical by 10.4% in the 4th quarter. MTM Investment Management LLC now owns 18,575 shares of the company's stock worth $139,000 after purchasing an additional 1,750 shares during the period. Northwest & Ethical Investments L.P. lifted its stake in shares of Profound Medical by 94.9% in the 4th quarter. Northwest & Ethical Investments L.P. now owns 46,200 shares of the company's stock valued at $346,000 after purchasing an additional 22,500 shares in the last quarter. Vestcor Inc purchased a new stake in shares of Profound Medical during the 4th quarter worth about $376,000. Finally, Truist Financial Corp purchased a new stake in shares of Profound Medical during the 4th quarter worth about $376,000. Hedge funds and other institutional investors own 47.86% of the company's stock.

Remove Ads

Profound Medical Trading Down 2.7 %

NASDAQ PROF traded down $0.18 during mid-day trading on Wednesday, hitting $6.50. The company's stock had a trading volume of 31,067 shares, compared to its average volume of 51,820. The firm has a market capitalization of $195.26 million, a P/E ratio of -4.85 and a beta of 0.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16. Profound Medical Corp. has a 52-week low of $5.63 and a 52-week high of $11.42. The stock's fifty day simple moving average is $6.85 and its two-hundred day simple moving average is $7.39.

Profound Medical (NASDAQ:PROF - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.11. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. The business had revenue of $4.18 million for the quarter, compared to the consensus estimate of $5.92 million. Research analysts expect that Profound Medical Corp. will post -1.12 EPS for the current year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.